B. Riley analyst Mayank Mamtani initiated coverage of Theravance Biopharma (TBPH) with a Buy rating and $28 price target The firm says Theravanc is a fully integrated biopharma company with a track record of discovering, developing and commercializing respiratory therapies. The company, after monetizing non-core asset Trelegy, is well positioned to benefit from a recent strategic review process aimed at unlocking shareholder value, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBPH:
- Promising Outlook for Theravance Biopharma: Buy Rating Backed by Phase 3 CYPRESS Trial Developments
- Theravance Completes Enrollment in Phase 3 CYPRESS Study
- Theravance Biopharma completes enrollment in CYPRESS study
- Theravance Biopharma Settles Patent Dispute with Cipla
- Theravance Biopharma: Strong Product Performance and Promising Growth Prospects Justify Buy Rating